Integral Investment Advisors Inc. Has $603,000 Stake in Zoetis Inc. $ZTS

Integral Investment Advisors Inc. raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 7.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,865 shares of the company’s stock after buying an additional 280 shares during the quarter. Integral Investment Advisors Inc.’s holdings in Zoetis were worth $603,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of ZTS. Nuveen LLC bought a new position in Zoetis during the 1st quarter worth approximately $616,375,000. Mackenzie Financial Corp boosted its position in shares of Zoetis by 4,158.3% during the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock worth $300,481,000 after purchasing an additional 1,782,110 shares in the last quarter. Polen Capital Management LLC grew its holdings in shares of Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after buying an additional 1,313,653 shares during the period. Amundi increased its position in shares of Zoetis by 30.8% in the 1st quarter. Amundi now owns 3,595,628 shares of the company’s stock valued at $575,691,000 after buying an additional 846,909 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd increased its position in shares of Zoetis by 475.9% in the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company’s stock valued at $148,228,000 after buying an additional 743,926 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Up 1.1%

NYSE:ZTS opened at $147.57 on Tuesday. The company has a market cap of $65.40 billion, a P/E ratio of 25.40, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $184.40. The business has a 50 day moving average price of $148.08 and a two-hundred day moving average price of $153.52. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period last year, the company earned $1.56 earnings per share. The firm’s revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio is currently 34.42%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ZTS shares. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Argus reissued a “buy” rating and set a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. UBS Group dropped their target price on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a report on Monday, October 20th. Finally, Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.